Last reviewed · How we verify
Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction (Met-PEF)
Met-PEF will be a randomized, double-blind, placebo-controlled trial to examine the effects of 20 weeks of 1500 mg/day of metformin on physical function, quality of life (QOL), microbiome diversity, leaky gut, and systemic inflammation in patients with 86 older patients with heart failure with preserved ejection fraction (HFpEF).
Details
| Lead sponsor | Wake Forest University Health Sciences |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 86 |
| Start date | 2022-01-04 |
| Completion | 2026-04-16 |
Conditions
- Heart Failure With Preserved Ejection Fraction
Interventions
- Metformin
- Placebo
Primary outcomes
- Peak VO2 — Week 20
Peak VO2 (ml of O2 relative to kg of body weight per minute \[ml/kg/min\]) is a measure of peak oxygen capacity during exercise, is a standardized, objective, reproducible and valid measure of exercise capacity.
Countries
United States